Nicholas Lydon is Director at Blueprint Medicines Corp (BPMC). They have made 10 open-market trades across 2 companies since 2017, most recently 2024-06-12.
CIK 0001639935
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $250K since 2017, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BPMC | SELL | 2020-10-01 | 2020-10-05 | $93.08 | $1.8M | +5.3% | +6.2% | +9.7% |
| BPMC | SELL · 10b5-1 | 2020-09-17 | 2020-09-21 | $80.00 | $40K | +14.1% | +21.7% | +47.8% |
| BPMC | SELL | 2020-07-06 | 2020-07-08 | $80.45 | $4.1M | -0.0% | -5.1% | +23.1% |
| BPMC | SELL | 2020-07-01 | 2020-07-06 | $80.16 | $661K | -1.4% | -3.7% | +21.2% |
| BPMC | SELL · 10b5-1 | 2020-06-23 | 2020-06-25 | $80.00 | $32K | +0.1% | -3.6% | +14.1% |
| BPMC | SELL | 2020-06-22 | 2020-06-23 | $80.29 | $2.1M | +1.7% | -2.6% | -0.8% |
| BPMC | SELL | 2019-06-13 | 2019-06-17 | $90.36 | $2.3M | -3.2% | +0.6% | -15.4% |
| BPMC | SELL | 2019-06-12 | 2019-06-14 | $84.77 | $2.1M | -6.9% | -1.1% | -18.5% |
| ANAB | SELL | 2018-04-16 | 2018-04-18 | $86.78 | $5.4M | +1.9% | -4.8% | -20.8% |
| BPMC | SELL | 2018-02-28 | 2018-03-02 | $87.89 | $4.4M | +5.0% | -6.8% | -11.4% |
| BPMC | SELL | 2017-03-14 | 2017-03-16 | $40.05 | $2.8M | +5.0% | +14.3% | -3.7% |
| ANAB | BUY | 2017-01-31 | 2017-01-31 | $15.00 | $250K | +30.5% | +32.0% | +51.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.